Trials / Completed
CompletedNCT04676607
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
SHR7390 in the Treatment of Metastatic Hormone-Resistant Prostate Cancer That Failed Previous Docetaxel and New Endocrine Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
- Sex
- Male
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
This trial aims to prospectively assess the safety and efficiency of SHR7390 in metastatic castration-resistant prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR7390 | SHR7390 |
Timeline
- Start date
- 2020-12-17
- Primary completion
- 2023-06-12
- Completion
- 2023-06-12
- First posted
- 2020-12-21
- Last updated
- 2023-06-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04676607. Inclusion in this directory is not an endorsement.